Aimery de Gramont

Aimery de Gramont, MD is a Professor of Oncology at Sorbonne Université and the longtime Head of the Medical Oncology Department at Institut Hospitalier Franco-Britannique in Levallois-Perret, France. He is one of the most consequential figures in the history of colorectal cancer chemotherapy, widely credited as the inventor of the FOLFOX regimen and the LV5FU2 infusional fluorouracil/leucovorin schedule that formed its backbone. In the early 1990s, Dr. de Gramont developed and championed infusional fluorouracil schedules as superior to bolus 5-FU in colorectal cancer, a contribution that reshaped fluoropyrimidine delivery worldwide. He subsequently developed the FOLFOX regimen (oxaliplatin combined with LV5FU2), which he evaluated in a series of pivotal phase II and III trials through the Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) and MOSAIC cooperative groups. His 2000 publication in the Journal of Clinical Oncology established FOLFOX6 as a second-line standard in mCRC, and he subsequently led or co-led the MOSAIC trial demonstrating a survival benefit of adjuvant FOLFOX4 (oxaliplatin plus LV5FU2) in stage III colon cancer—one of the most significant advances in adjuvant CRC therapy of the past 25 years. Dr. de Gramont's contributions form the foundation of modern colorectal cancer chemotherapy practice. He is the recipient of numerous international honors and has been a leading voice in European and global oncology for more than four decades.